Patricia Dugan, MD
Epilepsy · New York, NYNPI 1467789107
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,833 of the $97,140 with a category attached, or 86.3%. Neuropace, Inc. accounts for 99.9% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $37,338, 3.1 times the $11,946 reported in 2019. Among epilepsy clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $809.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$97K
- Philips North America LLC$27
- Natus Medical Incorporated$25
- Smith+Nephew$23
- Sumitomo Pharma America, Inc.$14
Across 465 payments — averaging $402.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neuropace, Inc.$187K
What the payments were for
- Consulting fees$83,83386%
- Travel & lodging$10,14510%
- Food & beverage$3,1633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 116 | $97,051 |
| Philips North America LLC | 1 | $27 |
| Natus Medical Incorporated | 1 | $25 |
| Smith+Nephew | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$62,337
- RNS System$34,110
How this compares
$97,140 in reported general payments places this provider in the 95th percentile of 21 epilepsy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 105 | $182,921 |
| AptiomEslicarbazepine Acetate | 40 | $95,248 |
| BriviactBrivaracetam | 48 | $87,558 |
| EpidiolexCannabidiol (Cbd) | 16 | $77,711 |
| KeppraLevetiracetam | 21 | $58,187 |
| Lamictal XrLamotrigine | 12 | $49,585 |
| Qudexy XrTopiramate | 17 | $30,748 |
| TrileptalOxcarbazepine | 12 | $25,413 |
| Lamotrigine ErLamotrigine | 61 | $24,856 |
| VimpatLacosamide | 16 | $22,844 |
| LyricaPregabalin | 12 | $12,415 |
| Clobazam | 56 | $7,177 |
| Levetiracetam | 111 | $6,481 |
| Lacosamide | 99 | $6,039 |
| Tegretol XrCarbamazepine | 12 | $3,518 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in New York
- Daniel FriedmanNew York$66K
- Christopher ElderNew York$41K
- Hai ChenNew York$1K
- Priya PurushothamanNew York$1K
- Robert McInnisNew York$801
- Kyung KimNew York$556
- Robert GloverBuffalo$88K
- Sheryl HautBronx$61K
- Benjamin BlondStony Brook$40K
- Andres Rodriguez-RuizBrooklyn$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.